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Abstract
The aim of this work is to develop a compact point-of-care device as a proof of concept of a novel read-out methodology than enhances
the biosensing response by improving significantly the LoD and makes the interrogation process simple and more reliable. The measured
signal is called Increase Relative Optical Power (IROP) and is a function of the optical power or irradiance for a certain optical interrogation
band of two interferometers (reference and signal). The functionality of this device is validated by performing standard immunoassays and
comparing these results with high resolution spectrometry.
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Point-of-care  device description
Theoretical simulation
IROP signal quantifies the accumulation or recognition
of biomolecules onto the sensing surface and is given
by the optical power of two different interferometers
(IF) - reference and signal, for a given spectral range.
Comparative results: Anti-IgG_IgG immunoassay results
Bio-Kits
The signal IF is based on Fabry-Perot
Interferometers with thin layers of
SU8 and nitrocellulose. The chip
surface is bio-functionalized to
detect the target biomolecule in an
specific way. The chip is set in a glass
substrate and the sample is drop in a
well defined with a vinyl sticker.
Conclusion
A is the area by the reference chip. C is
the area defined by the signal chip
when the biofilm thickness is 0 nm. B
represents the shift in the signal
interferometer for a biofilm thickness
of 40 nm.
Read-out device
In order to compare the device sensitivity, a standard immunoassay was
performed, based on the conjugated Anti-IgG_IgG. The antibody is
immobilized onto the sensing surface by direct absorption, incubating the
sample (50 μg/mL) during 12 hours at 37 degrees avoiding evaporation. The
blocking step is next (BSA- 3%) to avoid unspecific bounding of biomolecules.
Lately, several concentration of IgG were incubated onto the chip surface for
20 minutes at 37 degrees to obtain the calibration curve and the correlation
shown in the Figure.
Results are compared with a FT-VIS-NIR high-resolution spectrometer
Vertex 70 which experimental sensitivity is estimated in 29.2 cm-1/mg mL-1
and a LoD of 277.7 ng mL-1 . However, for the read out device described in
this work, the resolution is estimated in 1.92 %ΔIROP/mg mL-1 and the
LoD for the same transducers and for the same immunoassay resulted in a
value of 25.5 ng mL-1. Therefore, the IROP methodology significantly
enhances the LoD in more than one order of magnitude.
The novel read-out methodology (IROP) presented in this work will allow to develop cost-effective, compact and
easy-to-use Point-of-care devices with better performance in terms of LoD and time in comparison with high
resolution spectrometry. The PoC based on IROP provides a quantitative result in only 2 minutes with 50 μL of sample
for the Anti-IgG_IgG immunoassay and reaches a LoD of 25,5 ng·mL-1. This biosensing system is therefore feasible to
be applied for ideal and reliable PoC devices.
